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Abstract 
Background: Metabolic syndrome (MetS) becomes a serious society health problem. The main risk factors of MetS 
are related to the increased risk of cardiovascular diseases, appearance of stroke, type 2 diabetes mellitus and the 
growing risk of mortality. MetS stimulates the appearance of early atherosclerosis, its progress and accelerates the 
frequency of cardiovascular complications related to atherosclerosis and diabetes mellitus.
Objective:  To evaluate the risk of cardiovascular events (myocardial infarction, stroke) among the individuals with 
MetS in a 10 year prospective study; to identify MetS components that determine risk and character of cardiovascular 
events.
Methods: The study design was prospective. It was started in 2003 to assess the risk factors, clinical components, 
diagnostic criteria of MetS. At the second stage in 2013 the individuals were repeatedly invited to evaluate cardiovas-
cular pathology that was confirmed by cardiologist and neurologist. The 45 years old and older citizens of Lithuanian 
district participated in the study. 1115 individuals (562 men and 553 women) were randomly selected in 2003. 538 
respondents: 278 (51.70 %) men and 260 (48.30 %) women participated in the repeated study in 2013.
Results: During the study myocardial infarction (MI) was confirmed to 7.43 % individuals taken part in the study, 
stroke—to 4.28 % individuals. The odds’ ratio (OR) of MI between individuals with MetS and without MetS was 1.80 
(95 % CI 1.67–1.97), p < 0.05. The OR of stroke for individuals with MetS and without MetS was 2.05 (95 % CI 1.21–2.54), 
p < 0.05. The OR of MI between men with abdominal obesity and identified MetS was 3.12 (95 % CI 2.77–3.53), 
p < 0.05. The OR of stroke between men with low level of high density lipoprotein cholesterol and identified MetS 
was 4.98 (95 % CI 4.40–5.65), p < 0.05. The OR of stroke between men with hypertriglyceridemia and identified MetS 
was 8.43 (95 % CI 7.45–9.54), p < 0.05.
Conclusions: Individuals with identified MetS have 1.80 and 2.05 times higher statistically significant probability, 
respectively, for MI and stroke events, than individuals without MetS. Separate components or MetS increase risk of 
cardiovascular events in men: abdominal obesity increases risk of MI, and low level of high density lipoprotein choles-
terol and hypertriglyceridemia increase risk of stroke.
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Background
Cardiovascular diseases remain the leading cause of 
the death in industrialised countries and in many of the 
developing countries in parallel with industrialisation, 
urbanisation and changes of life style. The increase of 
cardiovascular events in economically developed coun-
tries determine the risk factors of coronary heart disease 
(CHD): hypertension, abdominal obesity, dyslipidemia, 
failure of glucose metabolism that are caused by seden-
tary lifestyle, dietary changes, stress, smoking and elder 
age. MetS, connecting 3–5 risk factors of CHD, increases 
frequency of cardiovascular events especially among the 
Open Access
*Correspondence:  brauklyte@yahoo.com 
Institute of Endocrinology, Lithuanian University of Health Sciences, 
Eiveniu 2, 50009 Kaunas, Lithuania
Page 2 of 7Kazlauskienė et al. Diabetol Metab Syndr  (2015) 7:102 
elderly population [1]. Some studies state that MetS is 
more frequent 1.50–2.00 times to individuals with CHD. 
MetS significantly increases frequency of cardiovascular 
events, their progress and risk of consequences [2, 3]. 
The risk of CHD is 7 times higher among individuals with 
MetS and diagnosed diabetes mellitus [4].
Studying the relation between MetS and increased risk 
of CHD among the 40-year old individuals (more than 
1/3 of individuals with hypertension or low high density 
lipoprotein cholesterol (HDLP)) there was identified that 
risk to develop CHD is higher to individuals with MetS 
(p < 0.001) [5]. Among the individuals participated in the 
study, 55 had 10 % higher risk to get cardiovascular event 
in a 10-year time, and MetS was identified to 33 (60 %) 
of them. According to the study data, individuals with 
identified hypertriglyceridemia had a higher risk of car-
diovascular events or there were more risk factors to the 
individuals with increased low density lipoprotein cho-
lesterol (LDLP) level (p < 0.05).
According to the data of epidemiological and clinical 
studies, separate MetS component is independent risk 
factor of CHD [6–9]. Some studies analyse the relation 
between separate MetS components and risk of cardio-
vascular diseases [10–12]. Influence of separate MetS 
components to development of CHD differs but the 
greater number of MetS components leads to the higher 
risk of CHD [12]. On the base of Lithuanian study data, 
the OR of CHD to individuals with 4–5 components and 
without any component of MetS is 7.20 (95 % CI 2.05–
26.6) in men’s group and 4.14 (95  % CI 1.70–10.2) in 
women’s group; comparing the individuals with 4–5 com-
ponents and 1–3 components, the OR was 2.32 (95 % CI 
1.01–5.23) in men’s group and 1.76 (95 % CI 0.98–3.15) in 
women’s group [13].
The study aim
To evaluate the risk of cardiovascular events to individ-
uals with identified MetS in 10-year time; to clarify the 
MetS components leading risk and character of cardio-
vascular events.
Methods
The study has been approved by Kaunas Regional Bio-
ethics Committee, Lithuania (No. BE-2-34/2011, No. 
PI-22/2013).
The study was started in 2003 to evaluate the risk fac-
tors, clinical components, diagnostic criteria of MetS. 
1115 (562 men and 553 women) adults of permanent 
population (living in town and village)from Lithuanian 
district were randomly selected to participate in the 
study at the first stage in 2003.
In 2011 year 966 invitations were sent to participate 
at the second stage of the study. The invitations were 
sent by post-office. 10.40 % individuals from the starting 
point of the study had died, 2.96 % had moved to other 
living places. 538 (278 men and 260 women, accord-
ingly 51.70  % and 48.30  %) individuals participated at 
the second stage in 2011–2013. The rate of responses 
was 55.70 %. Individuals were asked to arrive for testing 
without taking any food for at least 12 h. Individuals pre-
sented the written agreement to participate in the study. 
The questionnaire with demographic, life and health his-
tory data was filled, assessed the objective clinical con-
dition, anthropometric data, blood pressure measured, 
fasting glycaemia and lipids panel were assessed by labo-
ratory tests.
Height and weight of all the participants were meas-
ured. Both body mass and height were measured using 
standardised and calibrated medical electronic scales 
and height meter. Body mass index (BMI) was esti-
mated using the following formula: weight, kg/height, 
m2. Waist circumference was measured. Measurements 
were performed at median line of waist between the 
lower rib margin and wing of ileum was measured while 
the patient held his/her breath. Arterial blood pressure 
(ABP) was measured according to recommendations for 
correct ABP measurement based on the Guidelines of the 
European Society of Hypertension, 2007 [14]. After the 
patient was seated for approximately 5 min in quiet envi-
ronment, standard cuff was put on his forearm at heart 
level. To assess the circulation of carbohydrates there was 
done a fasting glucose test of vein blood plasma using the 
means of biochemical analyser BIOSEN C–line. HDLP 
cholesterol was measured using CHOD-PAP ferment 
photometric method; triglycerides—GPO–PAP were 
measured using ferment photometric method [15, 16].
MetS was assessed according to National Cholesterol 
Education Program III modified criteria [17]. Subjects 
were included in MetS group when at least three symp-
toms of listed below were confirmed:
1. Waist circumference in men >102  cm, in women 
>88 cm;
2. Systolic blood pressure ≥130  mm Hg and/or dias-
tolic blood pressure ≥85 mm Hg or anti hypertensive 
medications are used;
3. Blood glucose level (fasting) ≥5.6 mmol/l;
4. Triglycerides (TG) ≥1.7 mmol/l or special treatment 
to lower TG level is applied;
5. HDLP cholesterol <1.03  mmol/l in men and 
<1.29 mmol/l in women.
MI was identified by cardiologist on the base of clini-
cal angina syndrome, newly appeared typical ischaemic 
changes in electrocardiogram and increase of troponin I 
concentration.
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Ischaemic stroke was confirmed by neurologist on the 
base of clinical features and head brain computer tomog-
raphy scan.
Statistical analysis
Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS v. 20.0). The data was 
presented as average, standard deviation. To compare the 
differences between groups with normal distribution Stu-
dent t test was used. To compare the differences between 
averages when distribution was not normal or the group 
was less than 20 Mann–Whitney U test was used. To 
compare frequency in different groups Chi-square (preci-
sion Fisher criterion) criterion was used. The probability 
of a certain variable, in case of a certain factor, was evalu-
ated by calculating the odds ratio (OR) and its 95 % con-
fidence interval (CI) using the one way logistic regression 
analysis. The significant level of p < 0.05 was checked as 
statistical significant.
Results
Clinical characteristics of the individuals taken part in the 
study
538 individuals have taken part in the repeated study: 278 
(51.70 %) men and 260 (48.30 %) women, p > 0.05. The 
main characteristics of the individuals are presented in 
the Table 1. The age of individuals was 55–92 and there 
was not significant difference of the age in men and 
women’s groups. Due to genders’ constitutional peculiar-
ities, anthropometric data of men and women was signif-
icantly different. Comparing genders, obesity among the 
women was more frequent. MetS was identified on the 
base of National Cholesterol Education Program Adult 
Treatment Panel III (NCEP/ATP III). According to the 
data of analysis and objective investigation of individuals, 
MetS was identified to 43.90 % individuals: 18.60 % men 
and 25.30  % women, p  <  0.05. According to the data of 
the study MetS was more frequent among the women.
Frequency of cardiovascular events among the individuals 
taken part in the study
In a 10 year period MI was confirmed to 7.43 % individu-
als, stroke diagnosis was confirmed to 4.28 %. According 
to the study data MI is more frequent among the indi-
viduals with MetS than without MetS, respectively 9.75 
vs. 5.63  %, p  >  0.05. Stroke was confirmed more often 
to individuals with MetS than to ones without MetS, 
accordingly 5.93 vs. 2.98 %, p > 0.05. Comparing the fre-
quency of MI among the men and women with MetS, the 
pathology was confirmed more frequent to the women 
than men, accordingly 10.30 vs. 9.00  %, p  >  0.05. Com-
paring the frequency of stroke in the similar group of 
individuals (men and women with identified MetS), the 
significant difference was not observed, 5.15 vs. 7.00  %, 
p > 0.05. Analysing the data of MI, the frequency among 
the different genders’ individuals without MetS, MI was 
confirmed more often to men than women, respectively 
7.70 vs. 5.44  %, p  >  0.05. Stroke was confirmed more 
often to men than women, respectively 4.49 vs. 2.18  %, 
p > 0.05. However, difference was of no statistical signifi-
cance, probably due to too few cases.
The OR of MI between individuals with MetS and with-
out MetS was 1.80 (95 % CI 1.67–1.97), p < 0.05. The OR 
of stroke for individuals with MetS and without MetS 
was 2.05 (95 % CI 1.21–2.54), p < 0.05.
Using the method of logistic regression there was eval-
uated the relation between MetS components and cardi-
ovascular events (Tables 2, 3).
To men with waist circumference >102 cm probability 
of MI is 3.12 times higher (95 % CI 2.77–3.53) than with 
identified MetS, p < 0.05.
Probability of MI to men with identified hypergly-
caemia and identified MetS is 2.62 (95 % CI 2.32–2.96), 
p  >  0.05. However, difference was not statistically 
significant.
Probability of MI to women with waist circumfer-
ence > 88 cm and identified MetS is 4.36 (95 % CI 3.84–
4.96), p > 0.05.
Probability of MI to women with identified low HDLP 
cholesterol level (<1.29  mmol/l) and identified MetS is 
3.09, p > 0.05.
Table 1 Characteristics of the study sample
n the number of tested individuals, m average, SD standard deviation, p 
significance level, BMI body mass index, SBP systolic blood pressure, DBP 
diastolic blood pressure, MetS metabolic syndrome, TG triglycerides, MI 
myocardial infarction, HDLP high density lipoprotein cholesterol
* p the exact Fischer test
Characteristics Men, n = 278 Women, n = 260 p
Age (years), m ± SD 70.73 ± 8.56 70.35 ± 8.3 >0.05
Height (cm) 170.31 ± 6.78 158.31 ± 17.22 <0.05
Weight (kg) 82.80 ± 14.82 77.05 ± 16.13 <0.05
BMI (kg/m2) 28.50 ± 4.49 31.05 ± 5.91 <0.05
Waist circumference (cm) 101.58 ± 13.24 97.28 ± 14.22 <0.05
SBP (mmHg) 151.54 ± 21.24 152.73 ± 19.57 >0.05
DBP (mmHg) 88.12 ± 9.51 88.76 ± 10.48 >0.05
Fasting blood glucose 
(mmol/l)
4.9 ± 0.70 4.81 ± 0.71 <0.05
HDLP cholesterol (mmol/l) 1.4 ± 0.50 1.42 ± 0.44 <0.05
TG (mmol/l) 1.28 ± 0.92 1.3 ± 0.62 <0.05
Frequency of MetS, n (%) 100 (35.97) 136 (52.31) <0.05
Cardiovascular events (MI 
and stroke), n (%)
35 (12.59) 28 (10.77) >0.05
Frequency of MI, n (%) 21 (7.55) 19 (7.31) >0.05
Frequency of stroke, n (%) 14 (5.04) 9 (3.46) <0.05*
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Probability of stroke to men with identified hypertri-
glyceridemia is 8.43 times (95  % CI 7.45–9.54) higher 
than to men with identified MetS, p < 0.05. Probability of 
stroke to men with identified hyperglycaemia and iden-
tified MetS was 6.80 (95  % CI 6.01–7.70), p  >  0.05. OR 
of stroke to men with identified low HDLP cholesterol 
level (< 1.03 mmol/l) was 4.98 times (95 % CI 4.40–5.64) 
higher than to men with identified MetS, p < 0.05.
OR of stroke to women with identified hyperglycae-
mia and identified MetS was 4.06 (95  % CI 3.57–4.62), 
p > 0.05.
Probability of MI to individuals with increased waist 
circumference is 1.50 times (95  % CI 1.09–2.08) higher 
than probability of stroke.
Employing the method of logistic analysis, the cor-
relation between MetS components and cardiovascu-
lar pathology in different (men/women) genders was 
evaluated.
It was evaluated the OR of MI in regard to the num-
ber of MetS components between genders. OR of MI 
to men with 2 MetS components is 1.38 times (95  % 
CI 1.22–1.57, p =  0.309) higher than to women. OR of 
stroke to men with 2 MetS components is 1.85 times 
(95 % CI 1.63–2.10, p = 0.021) higher than to women. OR 
of stroke to men with 3 MetS components is 1.37 times 
(95 % CI 1.21–1.56, p = 0.038) higher than to women.
It was evaluated the number of MetS components 
which influence appearance of cardiovascular events. 
Analysis was done to both genders separately. The 
results are presented in the Table  4. Stroke was mostly 
experienced in men with identified 3 components of 
MetS—2 (5.89 %) and MI was mostly experienced in men 
with 4 components, respectively 2 (18.19  %). Women 
experience cardiovascular events (stroke or MI) in cases 
with identified 4 components of MetS, respectively 2 and 
4 (15.39 vs. 30.77 %).
Discussion
Recently the new statement, that ageing and MetS 
have different influence on men and women genders, is 
appearing more and more often. The different ageing of 
both men and women blood-vessels’ was acknowledged 
in 2010 after the Arterial ageing study [18].
According to the data of some studies cardiovascu-
lar diseases’ (CVD) risk related to MetS is higher to 
women than men. It can be accounted for women arter-
ies’ tightness but there is a lack of evidence to confirm 
the statement. Moreover, the data of different studies are 
contradictory. The developing tightness of arteries due 
to MetS could be buttressed up by chronic inflamma-
tion and dysfunction of endothel [19–21]. This is prob-
ably due to the increased risk of CVD that is typical to 
the state. Studies ascertained have shown that women are 
more influenced by MetS to get atherosclerosis [22, 23].
R. Kawamoto and co-authors after researching 388 
men and 480 women ascertained that early atheroscle-
rosis among the patients with MetS is identified only to 
women. However, epidemiology research has shown that 
men have atherosclerotic plates more often than women 
[24]. The scientists tend to explain this difference as 
Table 2 OR of MI to individuals with identified MetS or an only component of MetS
OR odds ratio, p significance level, CI confidence interval, MetS metabolic syndrome
Components of MetS Men with confirmed MetS,  
OR, [95 % CI], p
Women with confirmed, 
MetS, OR, [95 % CI], p
Waist circumference 3.12 [2.77–3.53], 0.049 4.36 [3.84–4.96], 0.131
Hypertension 0.52 [0.47–0.59], 0.253 0.92 [0.81–1.05], 0.916
Hyperglycaemia 2.62 [2.32–2.96], 0.367 –
Low level of high density lipoprotein cholesterol 1.36 [1.21–1.54], 0.649 3.09 [2.72–3.51], 0.071
Elevated triglycerides 1.69 [1.50–1.91], 0.390 1.05 [0.93–1.20], 0.935
Table 3 OR of stroke when MetS or an only its component is identified
OR odds ratio, p significance level, CI confidence interval, MetS metabolic syndrome
Components of MetS Men with confirmed MetS,  
OR, [95 % CI], p
Women with confirmed 
MetS, OR, [95 % CI], p
Waist circumference 2.50 [2.21–2.83], 0.281 1.74 [1.54–1.99], 0.618
Hypertension – 0.82 [0.72–0.94], 0.858
Hyperglycaemia 6.80 [6.01–7.70], 0.057 4.06 [3.57–4.62], 0.190
Low level of high density lipoprotein cholesterol 4.98 [4.40–5.64], 0.034 1.35 [1.19–1.54], 0.790
Elevated triglycerides 8.43 [7.45–9.54], 0.004 1.89 [1.67–2.16], 0.482
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influence of hormones. During the menopause women 
lose the influence of oestrogen which reduces athero-
sclerosis. The deficit in oestrogens for elderly women 
due to menopause is related to complications of CVD. It 
is stated that normal physiological concentration of oes-
trogens prevent elderly men’s heart and blood-vessels’ 
system. Testosterone in men’s organism produces oes-
trogens [25]. Therefore, MetS causes negative gender 
hormones alteration that changes CVD pathogenesis and 
stimulates early atherosclerosis for both genders [26].
According to the prospective study data, comparing 
the prevalence of MI among the adults population, the 
pathology of MI was more frequently confirmed to indi-
viduals with MetS. It was confirmed more frequently to 
women than men, respectively 10.30 vs. 9.00 %, p > 0.05. 
Comparing the prevalence of stroke in a similar group 
of individuals, significant difference was not observed, 
accordingly 5.15 vs. 7.00 %, p > 0.05.
Nowadays there is done meta analysis of 87 studies that 
involved 951,083 individuals. The results showed that 
individuals with identified MetS have twice higher risk to 
develop cardiovascular diseases. Mortality to individuals 
with identified MetS is higher 1.50 times [27].
According to our study, individuals with identified 
MetS have 1.80 (95  % CI 1.67–1.97) and 2.05 (95  % CI 
1.21–2.54) times higher statistically significant probabil-
ity, respectively, for MI and stroke events, than individu-
als without MetS.
So far there is no a generally accepted view on the vari-
ous risk factors that compound MetS. The risk factors’ 
aggression, the frequency in combinations are under 
investigation, it is unclear which component of the com-
bination is more important, which appeared first and 
caused other factors leading to the occurrence. Many 
researchers indicate that glucose metabolism disorder 
raises a higher risk of CHD in combination of MetS com-
ponents. Insulin resistance and abdominal fat accumu-
lation associated with lipoprotein metabolism disorders 
(atherogenic dyslipidemia) are consequences of glucose 
metabolism disorder. According to the data of the pro-
spective study it was evaluated the risk of cardiovascular 
events by identified/not identified MetS or identified a 
component of MetS. The OR of MI to men and women 
with identified abdominal obesity is respectively 3.12 
(95 % CI 2.77–3.53) vs. 4.36 (95 % CI 3.84–4.96). It indi-
cates that MetS increases the possibility of MI. The OR of 
MI to men with identified hyperglycaemia is 2.62 (95 % 
CI 2.32–2.96). The OR of stroke to women with identified 
hyperglycaemia is 4.06 (95 % CI 3.57–4.62), to men—6.80 
(95 % CI 6.01–7.70). The study results demonstrate that 
the OR of cardiovascular events (MI or stroke) to indi-
viduals with an identified MetS component, especially 
with identified abdominal obesity or hyperglycaemia is 
higher than to individuals with confirmed MetS. Hyper-
glycaemia and abdominal obesity are stronger prognostic 
indexes in common population than syndrome as unit.
There are some data showing that increase of cardio-
vascular diseases is related directly with a greater number 
of syndrome components [10–12].
Beaver Dam study tested 4423 individuals aged 43–86 
without MetS at the starting point. The study ascertained 
the influence of MetS components to the risk of cardio-
vascular disease: the more components, the higher risk. 
The risk of cardiovascular diseases increased 6 times 
during 5 years period to individuals with identified 4 or 
more components [11]. In Japan, after researching 6182 
men aged 35–59 without confirmed cardiovascular dis-
ease at a starting point of the study, the risk of CVD dur-
ing 7  years of the research significantly increased as it 
was caused by increase of components number. The OR 
of CVD to men with an identified MetS component was 
4.98; 5.86; 9.98; p < 0.001 [12].
According to the prospective study data, stroke was 
mostly experienced in men with identified 3 components 
of MetS and MI was mostly experienced in men with 4 
components. Women experience cardiovascular events 
(stroke or MI) in cases with identified 4 components of 
MetS.
Table 4 Distribution of  MetS components which influence apperance of  cardiovascular events (stroke, MI) to  both 
genders
n the number of tested individuals, MetS metabolic syndrome, MI myocardial infarction
Cardiovascular  
events
MetS with 3 components, n (%) 
(n = men/women) (n = 34/57)
MetS with 4 components, n (%)  
(n = men/women) (n = 11/13)
MetS with 5 components, n (%) 
(n = men/women) (n = 2/2)
Men
 Stroke 2 (5.89) – 1 (50.00)
 MI 2 (5.89) 2 (18.19) –
Women
 Stroke 2 (3.51) 2 (15.39) –
 MI 4 (7.02) 4 (30.77) 1 (50.00)
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Large long-term (12-year observed 62,000 men and 
262,000 women) studies’, conducted in the United States, 
data were used to estimate the relationship between com-
mon and cardiovascular mortality and the BMI [28].
An obvious increase in total mortality was observed at 
a BMI over 25 kg/m2. CVD drastic increase in the mor-
tality was observed with BMI over 30 kg/m2. Gothenburg 
studies made in Sweden focused on the position of fat in 
the body, i.e. waist/hip ratio in touch with MI and stroke 
frequency. The results confirmed the hypothesis—MI 
and frequency of stroke among the patients with abdomi-
nal obesity was higher [29].
According to the study data, the OR of MI to individu-
als with increased waist circumference is 1.50 times (95 % 
CI 1.09–2.08) higher.
The significant influence of diabetes mellitus in MetS 
combinations indicates the fact that 65  % patients die 
from CVD, while MetS is identified to 66–86 % of indi-
viduals with diagnosed diabetes mellitus [30–33].
According to Kaunas Medical University Clinics’ Insti-
tute of Cardiology conducted research, MetS was iden-
tified to more than half patients with acute coronary 
syndrome. The most common components of MetS were 
the hypertension and abdominal obesity. There were 
identified one or two components of MetS to more than 
1/3 (36.50  %) patients with acute coronary syndrome; 
Combination of 3 components of MetS was identified to 
1/3 (29.20  %) of patients. Combination of 4–5 compo-
nents was identified to 1/3 (30.40 %) of patients. No one 
component of MetS was not identified to only 3.90 % of 
patients. Hypertension and abdominal obesity were iden-
tified in more than a half of events (57.80 %) and it was 
found in 2–5 components combinations [34].
According to the study, hyperglycaemia and hyper-
triglyceridemia were the most frequent components of 
MetS among the individuals who experienced cardiovas-
cular events. There was no significant difference between 
genders.
The study approved that MetS increases CVD risk. It is 
very important to identify MetS in time and evaluate the 
dominant component, and employ adequate non-phar-
maceutical and pharmaceutical treatment. Appropriate, 
adequate, individual treatment of MetS will prevent seri-
ous chronic diseases such as diabetes type 2 and CVD 
occurrence.
Conclusions
1. Individuals with identified MetS have 1.80 (95 % CI 
1.67–1.97) and 2.05 (95 % CI 1.21–2.54) times higher 
statistically significant probability, respectively, for 
MI and stroke events, than individuals without MetS.
2. Separate components or MetS increase risk of cardi-
ovascular events in men: abdominal obesity increase 
risk of MI, and low level of high density lipoprotein 
cholesterol and hypertriglyceridemia increase risk of 
stroke.
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